GRAIL Overview

  • Founded
  • 2015
Founded
  • Status
  • IPO Registration
  • Employees
  • 436
Employees
  • Latest Deal Type
  • M&A
  • (Announced)
  • Latest Deal Amount
  • $8B
Latest Deal Amount
  • Investors
  • 37

GRAIL General Information

Description

Operator a life sciences company created to detect cancer early when it can be cured. The company's the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection, enabling doctors to get products for the early detection of cancer.

Contact Information

Website
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Primary Office
  • 1525 O'Brien Drive
  • Menlo Park, CA 94025
  • United States
+1 (833) 000-0000

GRAIL Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GRAIL Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 21-Sep-2020 $8B 000 000 Announced Generating Revenue
5. IPO 09-Sep-2020 00000 000 Announced Generating Revenue
4. Later Stage VC (Series D) 06-May-2020 00000 000 00.000 Completed Generating Revenue
3. Later Stage VC (Series C) 21-May-2018 00000 00.000 00.00 Completed Generating Revenue
2. Early Stage VC (Series B) 22-Nov-2017 $1.21B $1.31B 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 08-Jan-2016 $100M $100M 00000 Completed Startup
To view GRAIL’s complete valuation and funding history, request access »

GRAIL Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 0.00
Series B 309,256,591 $0.001000 $4.01 $4.01 1x $4.01 41.14%
Series A 85,000,000 $0.001000 $1 $1 1x $1 11.31%
To view GRAIL’s complete cap table history, request access »

GRAIL Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator a life sciences company created to detect cancer early when it can be cured. The company's the power of high-in
Biotechnology
Menlo Park, CA
436 As of 2020
000
00 0000-00-00
000000&0 000

0000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000 000000000
Rehovot, Israel
00 As of 0000
000.00
0000000000 000.00

000000 0

on ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000000000 000000000
Vancouver, Canada
0 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GRAIL Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nucleix Venture Capital-Backed Rehovot, Israel 00 000.00 0000000000 000.00
000000 00000000 Venture Capital-Backed Vancouver, Canada 0 000.00 00000000000 000.00
0000 00000000 Venture Capital-Backed San Diego, CA 00 00000 000000000 - 00000
000000 Venture Capital-Backed Richmond Hill, Canada 00 000.00 000000 - 000 000.00
00000000000 000000 Venture Capital-Backed Birmingham, AL 00 00.000 0000000000 0 00.000
You’re viewing 5 of 38 competitors. Get the full list »

GRAIL Executive Team (12)

Name Title Board Seat Contact Info
Hans Bishop Chief Executive Officer & Board Member
Gautam Kollu Chief Commercial Officer
Joshua Ofman MD Chief Medical Officer & External Affairs
Jeffrey Huber Co-Founder & Vice Chairman
Aaron Freidin Vice President, Finance
You’re viewing 5 of 12 executive team members. Get the full list »

GRAIL Board Members (15)

Name Representing Role Since
Brook Byers Ph.D Self Board Member 000 0000
Catherine Friedman Self Chairman 000 0000
Hal Barron Self Board Member 000 0000
Hans Bishop GRAIL Chief Executive Officer & Board Member 000 0000
Jeffrey Huber GRAIL Co-Founder & Vice Chairman 000 0000
You’re viewing 5 of 15 board members. Get the full list »

GRAIL Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GRAIL Investors (37)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Canada Pension Plan Investment Board Limited Partner Minority 000 0000 000000 0
Public Sector Pension Investment Board Asset Manager Minority 000 0000 000000 0
The Mark Foundation for Cancer Research Corporation Minority 000 0000 000000 0
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
Ally Bridge Group PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 37 investors. Get the full list »

GRAIL Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 31-May-2017 000000000000000000 Biotechnology 0000000 00000
To view GRAIL’s complete acquisitions history, request access »